Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes

BJU International

Volumn 97, Issue 6, 2006, Pages 1300-1308

  Yamanaka, Kazuki ^a   Rocchi, Palma ^a   Miyake, Hideaki ^b   Fazli, Ladan ^a   So, Alan ^a   Zangemeister Wittke, Uwe ^c   Gleave, Martin E ^a,d  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antisense oligonucleotide; Apoptosis; Bcl 2; Bcl xL; Clusterin; OGX 011; Prostate cancer; siRNA

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CLUSTERIN; CRYSTAL VIOLET; PROTEIN BCL 2; PROTEIN BCL XL; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROTECTION; CELL STRAIN LNCAP; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME DEGRADATION; FLOW CYTOMETRY; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CLUSTERIN; FLOW CYTOMETRY; GENES, BCL-2; HUMANS; MALE; MITOXANTRONE; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 33745191622     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06147.x     Document Type: Article

References (49)

1. McLeod DG. Hormonal therapy: historical perspective to future directions. Urology 2003 61 ( Suppl. 2 3 7
2. Denis L, Murphy GP. Overview of Phase III trials on combined androgen treatment in patients with metastatic cancer. Cancer 1993 72 ( Suppl 12 3888 95
3. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 351: 1513 20
4. Tannock IF, de Wit R, Berry WR et al. the TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351: 1502 12
5. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005 23: 1 9
6. Nunez G, Clarke MF. The Bcl-2 family of proteins: regulators of cell death and survival. Trends Cell Biol 1994 4: 399 403
7. Chao DT, Korsmeyer SJ. Bcl-2 family: regulators of cell death. Annu Rev Immunol 1998 16: 395 419
8. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986 83: 5214 8
9. Boise LH, Gonzalez-Garcia M, Postema CE et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993 74: 597 608
10. McDonnell TJ, Troncoso P, Brisbay SM et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992 52: 6940 4
11. Colombel M, Symmans F, Gil S et al. Detection of the apoptosis- suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993 143: 390 400
12. Gleave M, Tolcher A, Miyake H et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999 5: 2891 8
13. Lebedeva I, Rando R, Ojwang J, Cossum P, Stein CA. Bcl-xL in prostate cancer cells: effect of overexpression and down-regulation on chemotherapy. Cancer Res 2000 60: 6052 60
14. Han Z, Chatterjee D, Early J, Pantazis P, Hendrickson EA, Wyche JH. Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switches expression from Bcl-2 to Bcl-xL. Cancer Res 1996 56: 1621 8
15. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathphysiologic considerations. Int J Biochem Cell Biol 1995 27: 633 45
16. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000 60: 170 6
17. Gleave ME, Miyake H, Zellweger T et al. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology 2001 58 ( Suppl. 2 39 49
18. Zellweger T, Chi K, Miyake H et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002 8: 3276 84
19. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg L, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002 50: 179 88
20. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005 7: 909 15
21. Dean NM, Bennett CF. Antisense oligonucleotide-based therapeutics for cancer. Oncogene 2003 22: 9087 96
22. Gleave M, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005 5: 468 79
23. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 1997 89: 1027 36
24. Ji J, Wernli M, Klimkait T, Erb P. Enhanced gene silencing by the application of multiple specific small interfering RNAs. FEBS Lett 2003 552: 247 52
25. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003 9: 1291 300
26. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 1998 78: 1035 42
27. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000 60: 2547 54
28. Jansen B, Schlagbauer-Wadle H, Brown BD et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998 4: 232 4
29. Miyake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Invest 2000 92: 34 41
30. Zangemeister-Wittke U, Leech SH, Olie RA et al. A novel bispecific antisense oligonucleotide inhibiting both Bcl-2 and Bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000 6: 2547 55
31. Gautschi O, Tschopp S, Olie RA et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic organs. J Nat Cancer Inst 2001 93: 463 71
32. Simoes-Wust AP, Schurpf T, Hall J, Stahel RA, Zangemeister-Wittke U. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res Treat 2002 76: 157 66
33. Olie RA, Hafner C, Kuttel R et al. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J Invest Dermatol 2002 118: 505 12
34. Jiang Z, Zheng X, Rich KM. Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J Neurochem 2003 84: 273 81
35. July LV, Beraldi E, So A et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 2004 3: 223 32
36. Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES. Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 2004 64: 1834 42
37. Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 2001 91: 846 50
38. Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 2000 141: 2257 65
39. Raffo AJ, Perlman H, Chen MW, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995 55: 4438 45
40. Miyake H, Monia BP, Gleave ME. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense Bcl-xL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer 2000 86: 855 62
41. Simonian PL, Grillot DA, Nunez G. Bcl-2 and Bcl-xL can differentially block chemotherapy-induced cell death. Blood 1997 90: 1208 16
42. Gottschalk AR, Boise LH, Thompson CB, Quintans J. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc Natl Acad Sci USA 1994 91: 7350 4
43. Arriola EL, Rodriguez-Lopez AM, Hickman JA, Chresta CM. Bcl-2 overexpression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis. Oncogene 1999 18: 1457 64
44. Gleave ME, Miyake H, Zangemeister-Wittke U, Jansen B. Antisense therapy: current status in prostate cancer and other malignancies. Cancer Metastasis Rev 2002 21: 79 92
45. Akgul C, Turner PC, White MR, Edwards SW. Functional analysis of the human MCL-1 gene. Cell Mol Life Sci 2000 57: 684 91
46. Bae J, Leo CP, Hsu SY, Hsueh AJ. Mcl-1S, a splicing variant of the antiapoptotic Bcl-2 family member Mcl-1, encodes a proapoptotic protein possessing only the BH3 domein. J Biol Chem 2000 275: 25255 61
47. Krajewska M, Krajewski S, Epstein JI et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996 148: 1567 76
48. Sedlak TW, Oltvai ZN, Yang E et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 1995 92: 7834 8
49. Chi KN, Eisenhauer E, Fazli L et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with prostate cancer. J Natl Cancer Inst 2005 97: 1287 9